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Abstract: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by
dysfunction and lymphocytic infiltration of the salivary and lacrimal glands. Besides the characteristic
sicca complaints, pSS patients can present a spectrum of signs and symptoms, which challenges
the diagnostic process. Various imaging techniques can be used to assist in the diagnostic work-up
and follow-up of pSS patients. Developments in imaging techniques provide new opportunities
and perspectives. In this descriptive review, we discuss imaging techniques that are used in pSS
with a focus on the salivary glands. The emphasis is on the contribution of these techniques to
the diagnosis of pSS, their potential in assessing disease activity and disease progression in pSS, and
their contribution to diagnosing and staging of pSS-associated lymphomas. Imaging findings of
the salivary glands will be linked to histopathological changes in the salivary glands of pSS patients.
Keywords: primary Sjögren’s syndrome; imaging; salivary gland; sialography; salivary gland
ultrasonography; magnetic resonance imaging; sialendoscopy; salivary gland scintigraphy; positron
emission tomography
1. Introduction
Primary Sjögren’s syndrome (pSS) is a chronic, systemic, autoimmune disease characterized by dry
mouth and dry eyes. As a heterogeneous systemic disease, many patients suffer from extraglandular
symptoms, and almost all organs can be involved [1]. Because of the heterogeneity of the disease,
pSS patients can present a broad spectrum of signs and symptoms, thereby making the diagnostic
process challenging. The characteristic sicca symptoms of mouth and eyes, however, remain the most
common manifestation of pSS. The dysfunction of the salivary glands and lacrimal glands is usually
associated with chronic inflammation. For this reason, salivary gland biopsies are part of the standard
diagnostic work-up, and the typical periductal lymphocytic infiltrates are an important criterion for
pSS [2]. However, taking biopsies is an invasive surgical procedure and cannot be performed in all
diagnostic centers. Imaging techniques, on the other hand, are noninvasive. It has been shown that
imaging techniques can assist in the diagnostic process of pSS [3]. Imaging techniques could also be of
value in assessing disease activity and detecting disease progression in pSS, which has already been
shown in other systemic autoimmune diseases [4].
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PSS patients have an increased risk of developing a non-Hodgkin’s lymphoma, mostly of
the mucosa-associated lymphoid tissue (MALT) type. The prevalence of lymphoma development in
pSS patients varies in different studies from 2.7% to 9.8% [5]. In pSS patients, MALT lymphomas most
commonly arise within the parotid glands, but they can also develop at other extranodal locations,
such as the lungs, lacrimal glands, or stomach [6–8]. Although the usefulness of imaging techniques
in the diagnosis, staging, and treatment response evaluation in lymphomas in general is widely
known [9,10], the value of imaging techniques in pSS-associated lymphomas is not yet clear.
In this descriptive review, we discuss the various imaging techniques used in pSS and link imaging
findings to histopathological changes that occur in the salivary glands. We review the potential
contribution of radiological and nuclear imaging techniques to the diagnostic work-up of pSS, and
their role in assessing disease activity and disease progression. We also discuss imaging techniques
that are currently used for the diagnosis and staging of pSS-associated lymphomas.
2. Diagnosis and Classification of pSS
Currently, there is no “gold standard” test or diagnostic criteria set to support diagnosis of this
heterogenous and multisystemic autoimmune disease [11,12]. Therefore, diagnosis of pSS is still based
on expert opinion, which relies on interpretation of a combination of several assessments. Although
there is no consensus yet which assessments are necessary for diagnosing pSS, the diagnostic work-up
can consist of different items, such as clinical examination, serological tests, oral and ocular tests,
imaging techniques, and histopathology of the salivary gland. In the past years, multiple classification
criteria sets were developed for pSS. These classification criteria were developed for research purposes,
to allow selection of well-defined and homogenous populations of pSS patients for clinical studies.
However, the terms diagnosis and classification in pSS are often used interchangeably since diagnosis
and classification depend on similar items/tests. Table 1 shows the items that are included in the various
classification criteria sets. In this review, we focus on the value of imaging techniques in the diagnostic
work-up of pSS. When we specifically discuss imaging techniques as items of classification criteria sets,
we add the term classification.
Table 1. Comparison of classification criteria sets for pSS [13].
2016-ACR-EULAR [14] 2012-ACR [15] 2002-AECG [16]
ESSDAI ≥ 1 + (Entry Criterion) − −
Sicca Symptoms + (Entry Criterion) − +
Salivary Gland Biopsy + + +
Serology
Anti-Ro/SSA + + +
Anti-La/SSB − + +
Antinuclear Antibodies − + −
Rheumatoid Factor − + −
Oral Signs
UWS ≤ 0.1mL/Min + − +
Sialography − − +
Scintigraphy − − +
Ocular Signs
Schirmer’s Test ≤ 5 + − +
Ocular Staining (OSS or vBv) + + +
ACR-EULAR: American College of Rheumatology-European League Against Rheumatism; ACR: American College
of Rheumatology; AECG: American European Consensus Group; ESSDAI: EULAR Sjögren’s Syndrome Disease
Activity Index; UWS: unstimulated whole saliva; OSS: ocular staining score; vBv: van Bijsterveld score.
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3. Histopathology of the Salivary Gland
For decades, salivary gland histopathology has played a major role in diagnosing pSS.
The characteristic finding within labial and parotid gland biopsies is the presence of infiltrates
around striated ducts, mainly consisting of B- and T-lymphocytes. From the number of periductal
foci (clusters of >50 lymphocytes) per 4 mm2, the focus score can be calculated, which is used in
classification criteria sets for pSS [2,14]. Another scoring system is the grading system by Chisholm
and Mason. In this grading system, stage 0, 1, and 2 indicate no, slight, or moderate infiltration with
less than one focus per 4 mm2, respectively. Stage 3 and 4 correspond with a positive focus score (≥1
focus per 4 mm2) [17]. Besides the presence of periductal foci, other characteristic features can be
found within the salivary glands of pSS patients, such as influx of IgG plasma cells and the presence
of lymphoepithelial lesions (LELs) and germinal centers [18–20]. LELs are defined as hyperplastic
ductal epithelial cells with infiltrating lymphocytes. LELs can eventually lead to complete obstruction
of ducts (Figure 1). In addition to these characteristic features, proportions of fibrosis and acinar
atrophy within salivary gland tissue are higher in pSS patients compared to controls [21,22]. There
is no agreement yet whether fatty infiltration is age-associated or specific for pSS [23,24]. Besides
their role in the diagnostic work-up of pSS, biopsies may also be used to assess prognosis (Table 2).
Higher focus score is associated with higher European League Against Rheumatism (EULAR) Sjögren’s
syndrome disease activity index (ESSDAI) scores, severe serological profiles, and an increased risk of
lymphoma development [25,26]. PSS-associated salivary gland MALT lymphomas are diagnosed on
histomorphological appearance (Figure 1) in combination with clonal analysis of immunoglobulin
heavy chain (IGH) variable(V)-diversity(D)-joining(J) (VDJ) gene segments [27]. The following sections
will discuss whether the characteristic histopathological findings correspond with imaging findings
found in pSS patients.
Figure 1. Histopathological features in parotid salivary glands of primary Sjögren’s syndrome patients
(A) Lymphocytic infiltrate located around a hyperplastic striated duct (lymphoepithelial lesion: LEL)
without obstructed lumen. Both (B) CD3+ T-lymphocytes and (C) CD20+ B-lymphocytes are present in
the periductal infiltrate and within the ductal epithelium. (D) Presence of a germinal center, which
was revealed by the presence of a cluster of ≥5 adjacent Bcl6-positive cells within a focus [28]. (E)
Immunoglobulin A (IgA) (red) and immunoglobulin G (IgG) (brown) staining shows a plasma cell shift
towards IgG plasma cells. (F) Salivary gland mucosa associated lymphoid tissue (MALT) lymphoma
biopsy, which shows a diffuse CD20+ B-lymphocytic infiltrate around lymphoepithelial lesions in
the absence of normal salivary gland parenchyma.
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Table 2. Contribution of imaging techniques to the diagnostic work-up and follow-up of pSS patients.
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Criteria for pSS Available
MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography; MALT: mucosa-associated lymphoid tissue. Plus and minus signs are entered as
follows: (+++) in case the imaging technique has an excellent contribution to the specific item, (++) for a good contribution, (+) in case the contribution is not yet clear or there is
contradictive data, and (−) in case there is no evidence for contribution of the imaging technique to the specific item.
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4. Radiology Techniques
4.1. Sialography
Sialography is a radiographic technique that visualizes the architecture of the ductal system
by using X-ray projections after injection of contrast medium. In pSS patients, sialography shows
sialectasis, which are collections of contrast material. The degree of sialectasis can be classified
according to the scoring system developed by Rubin and Holt [29] (Figure 2). Sialectasis may be
found at the location of cystic ductal dilatations in pSS patients. Another explanation could be that
sialectasis represents extravasation of contrast material into the glandular parenchyma. A possible
explanation for the leakage of contrast medium in pSS patients is dysfunction of tight junctions between
striated ductal cells, due to the presence of proinflammatory cytokines [30]. In addition to sialectasis,
sparsity of the ductal branching pattern can be found during sialography [3,31,32]. This could be
due to obstruction of the ductal system, as a result of lymphocytic infiltration and proliferation of
the ductal epithelium. However, direct associations with histopathological findings, such as the area of
lymphocytic infiltrate or presence of LELs, have thus far not been reported.
Figure 2. Findings on sialography. Sialographies of the parotid gland showing (A) no abnormalities in
a healthy subject, (B) punctate/globular sialectasis in a pSS patient, and (C) globular/cavitary sialectasis
in a pSS patient [29]. (D) Two-dimensional sialo-CBCT image and (E) three-dimensional sialo-CBCT
image of the parotid gland of a pSS patient, showing normal width of the primary duct, moderate
scarcity of ductal branches, and numerous diverse sialectasis. Thanks to Prof. D.J. Aframian and Dr. C.
Nadler and colleagues who provided the sialo-CBCT images.
Sialography has been used for diagnosing pSS for decades and shows moderate to high
sensitivity and specificity [3]. This technique was excluded from the 2016 American College of
Rheumatology/European League Against Rheumatism (ACR-EULAR) classification criteria (Table 1)
because of multiple drawbacks. It is an invasive technique with risk of complications and radiation
exposure. Furthermore, there are multiple contraindications like acute infection, acute inflammation,
and contrast allergy [3,31].
Alternative sialographic techniques have been developed, such as sialo-cone-beam computerized
tomography (sialo-CBCT) and magnetic resonance (MR) sialography. These techniques have an
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increased spatial resolution and provide three-dimensional, instead of two-dimensional, images of
the ductal system. Keshet et al. [33] described correlations between sialo-CBCT findings and clinical
data, such as xerostomia and serological parameters. However, since only 6 out of 67 sicca patients
fulfilled the American European Consensus Group (AECG) classification criteria for pSS in this cohort,
the usefulness of sialo-CBCT in pSS should be further investigated. MR sialography can identify
changes within the salivary glands without the injection of contrast medium. The typical finding in
pSS is the presence of multiple high-signal-intensity spots, which are thought to arise after leakage
of saliva from peripheral ducts. Kojima et al. [34] did not find correlations between MR sialography
findings and salivary flow rate, which can be explained by the fact that MR sialography visualizes
the ductal system instead of saliva-producing acinar cells. Although MR sialography seems to be more
sensitive to detect early disease, magnetic resonance imaging (MRI) provides more information on
pathological changes in the glandular parenchyma, as we describe below [35].
In conclusion, sialography is not commonly used in the diagnostic work-up and follow-up of pSS
anymore. Although alternative sialographic techniques such as sialo-CBCT and MR sialography have
been evaluated, their current role in the diagnostic work-up of pSS is limited.
4.2. Magnetic Resonance Imaging
The role of MRI of the salivary glands in pSS has been investigated during the past decades.
The characteristic finding in salivary glands of pSS patients is a heterogeneous signal-intensity
distribution on T1- and T2-weighted images. The multiple hypointense and hyperintense areas cause
a so-called salt and pepper appearance [34]. In the advanced stages of pSS, cystic changes can be
found with MRI, which are thought to arise from destruction of the salivary gland parenchyma and
the presence of fibrosis and fatty infiltration [3,31,36]. Although fat fractions in salivary glands seem to
increase with higher age and body mass index [37] and can account for 60% of the histological section
of the parotid gland in healthy individuals [38], imaging studies found that premature fat deposition
found on MRI images is associated with SS [39,40]. Histopathological studies, however, did not make
clear whether fatty infiltration is a specific feature of pSS or age-associated. Since biopsies do not
represent the entire gland, it remains difficult to correlate MRI findings to histopathological findings.
Although correlations between the focus score of the labial gland and MRI findings of the parotid gland
were found [41,42], further associations between MRI findings and histopathological findings, such as
the area of lymphocytic infiltration, fibrosis, and fatty infiltration, have not been investigated yet.
Although MRI showed added value in the diagnostic work-up of pSS by detecting pSS-specific
abnormalities of the salivary glands, this technique is not routinely applied in pSS. Findings on
MRI showed good agreement with salivary gland ultrasonography (SGUS). Since SGUS has several
advantages over MRI, such as its high spatial resolution in superficial organs and the fact that SGUS is
more easily accessible, SGUS is a better alternative for the diagnostic work-up of pSS [3,43].
Kojima et al. [34] demonstrated, in a group of pSS patients, that a higher degree of glandular
heterogeneity and a smaller volume of the parotid and submandibular glands on MRI images were
associated with lower stimulated and unstimulated salivary flow rates. These associations were even
more pronounced for the submandibular glands, compared to the parotid glands, indicating that
MRI findings of the submandibular glands can reflect hyposalivation. A possible explanation for
the differences in associations between both glands is that the function of the submandibular gland is
impaired earlier in the disease process than the function of the parotid gland [34,44,45]. Collection of
saliva from the individual glands would be a more direct approach to relate MRI findings with salivary
gland functioning in pSS. Similar to the MRI findings of Kojima et al. [34], lacrimal flow rates were
associated with lacrimal gland volumes of pSS patients. Lacrimal flow rates were lower in pSS patients
with atrophic lacrimal glands compared to patients with hypertrophic and normal-sized glands [46].
No studies have been performed to evaluate associations between MRI findings of the salivary glands
and systemic disease activity, but MRI is the most appropriate imaging technique to evaluate central or
peripheral nervous system involvement in pSS [47,48].
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MRI is also used for the evaluation of pSS-associated lymphomas in the head and neck region
(Figure 3). MRI findings of salivary and lacrimal gland MALT lymphomas vary. Findings that
have been described are glandular enlargement, (micro)cystic changes, and calcifications [49–51].
Zhu et al. [51] found that solid cystic appearances of MALT lymphomas can help to differentiate MALT
from non-MALT lymphomas. However, benign and malignant lesions of salivary and lacrimal gland
show overlap, which makes MRI a less reliable technique to differentiate between benign and malignant
disorders of the exocrine glands [3,52,53]. Despite the indolent nature of pSS-associated lymphomas,
these malignancies are able to disseminate to other mucosal sites or organs. MRI is used in local staging
of the disease, by assessing the ingrowth in adjacent structures and spread to lymph nodes or other
organs [50,54] (Table 2).
Figure 3. 18F-fluorodeoxyglucose (FDG) positron emmison tomography/computed tomography
(PET/CT) and magnetic resonance imaging (MRI) findings in a pSS patient with salivary gland mucosa
associated lymphoid tissue (MALT) lymphoma. (A) Whole-body FDG-PET showing high heterogeneous
FDG uptake in both parotid and submandibular glands. No other pathological lesions were found
(axillary and clavicular regions with increased uptake represent brown fat). (B) FDG-PET/CT image
showing pathological uptake in the parotid glands and physiological uptake in the tonsils. (C) MRI stir
sequence showing a pathological, heterogeneous aspect of both parotid glands. (D) Manually fused
FDG-PET/MRI image, showing pathological uptake in the parotid glands and physiological uptake
in the tonsils. (E) Whole-body FDG-PET and (F) FDG-PET/CT image after treatment, showing no
pathological uptake in the parotid glands, indicating complete remission.
Together, MRI is not often used in the standard diagnostic work-up of pSS. However, due to its
high spatial resolution, MRI is the most useful imaging technique for local staging of pSS-associated
salivary and lacrimal gland lymphomas.
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4.3. Salivary Gland Ultrasonography
Within the past decade, salivary gland ultrasonography (SGUS) has gained more and more
attention, and was proven to be effective for the detection of typical structural abnormalities in pSS [55,
56]. Furthermore, various studies demonstrated that addition of SGUS improves the performance and
feasibility of the 2016 ACR-EULAR classification criteria [57–60]. However, many different SGUS-based
scoring systems are available, and international consensus on which scoring system should be used is
lacking. This hampers addition of SGUS to the classification criteria [55,56]. Therefore, the Outcome
Measures in Rheumatology Clinical Trials (OMERACT) SGUS task force group has recently developed
ultrasound definitions and a novel SGUS scoring system with good and excellent inter and intraobserver
reliabilities, respectively [61]. Further studies should validate this scoring system before SGUS can be
added to the 2016 ACR-EULAR classification criteria.
Typical ultrasonographic abnormalities in pSS are hypoechogenic areas, hyperechogenic reflections,
and poorly defined salivary gland borders [55] (Figure 4). Mossel et al. [62] demonstrated that
the presence of hypoechogenic areas is the most important SGUS feature. However, it is still unknown
what these hypoechogenic areas reflect at a histological level. It has been suggested that hypoechogenic
areas consist of foci containing inflammatory cells. Histopathological foci, however, are smaller in
size compared to the hypoechogenic areas. Preliminary results of Mossel et al. [63] show a good
correlation between hypoechogenic areas and percentages of CD45+ leukocytic infiltrate. These results
indicate that, despite the differences in size, hypoechogenic areas are somehow associated with foci of
inflammatory cells. One explanation for this association could be that hypoechogenic areas originate
from leakage of saliva that is transported through the ductal system into the periductal infiltrate,
and eventually into the salivary gland parenchyma. Leakage of saliva from the ductal system can be
a comparable phenomenon to leakage of contrast medium during sialography, due to dysfunction
of tight junctions between striated ductal cells [30]. However, collections of saliva in the periductal
infiltrates or parenchyma are not commonly seen in salivary gland biopsies of pSS patients. Another
hypothesis is that the hypoechogenic areas represent fatty infiltration. However, fat tissue is most often
visible as a hyperechogenic instead of hypoechogenic area [64]. Furthermore, preliminary results of
Mossel et al. [63] show poor associations between hypoechogenic areas and the percentage of fat cells
in the total salivary gland parenchyma, which contradicts the latter hypothesis.
As described before, the area from which the parotid biopsies are taken may not be representative
for the ultrasonographic images. The biopsy is taken from the periphery of the gland, which does
not contain larger excretory ducts. Therefore, correlating histopathology to SGUS findings remains
difficult. A possibility to get a better understanding of what SGUS features in salivary glands of pSS
patients represent is taking ultrasound-guided core needle biopsies. A recent study by Baer et al. [65]
showed that taking core needle biopsies in pSS patients suspected of salivary gland lymphoma is
a safe and useful procedure. Although the morphology of core needle biopsies is inferior compared to
that of open biopsies, the core needle method allows biopsies to be taken from the exact location of
hypoechogenic areas or hyperechogenic reflections.
Another unresolved question is whether current SGUS scoring systems are sensitive enough
to assess (treatment-induced) differences that are seen histopathologically. Current SGUS scoring
systems use subjective categorical scales. Hypoechogenic areas, for instance, are scored on a 0–3
scale. Therefore, major changes need to occur in order to change from one category to another. This
could be an important drawback when using SGUS as an objective tool to assess disease progression
as well as to assess changes in salivary gland involvement in clinical trials [56,66]. Scoring SGUS
findings on a continuous scale and in a more objective way could increase the sensitivity to change.
A possible way to do this is by using image segmentation and artificial intelligence. HarmonicSS,
a multicenter and EU-supported project, is applying artificial intelligence to SGUS images in pSS.
Preliminary results show that, among the tested algorithms, the multilayer perceptron classifier is
the best performing algorithm. Since the HarmonicSS cohort will increase in size over time, further
validation will follow [56,67].
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Figure 4. Salivary gland ultrasonography findings in pSS. Presence of hypoechogenic areas and
hyperechogenic reflections in the (A) submandibular gland and (B) parotid gland of a pSS patient.
Despite the potential usefulness of SGUS in diagnosis and classification of pSS, the value of SGUS
to assess disease activity and disease progression and to detect salivary gland MALT lymphoma needs
to be established. SGUS scores seem to correlate with objective salivary gland function, as unstimulated
salivary flow rates were found to be lower in SGUS-positive patients, compared to SGUS-negative
patients [68–70]. Zabotti et al. [71] described that of all SGUS findings, the presence of hyperechogenic
bands was independently associated with salivary flow rates. Although they suggested that damage
of the glands is reflected by hyperechogenic bands, it is still unclear what these hyperechogenic
bands reflect at a histological level. Several studies showed associations between SGUS scores and
clinical parameters of disease activity, such as ESSDAI scores, IgG levels, and rheumatoid factor
(RF) levels [68,72–75]. In contrast, other studies did not find correlations between SGUS scores and
ESSDAI [69,76]. These discrepancies can be explained by differences in patient characteristics between
cohorts, and by the fact that severe salivary gland involvement might not reflect systemic disease
activity in all pSS patients.
Since previous studies found associations between SGUS findings and risk markers of lymphoma,
such as cryoglobulinemia, lymphopenia, and persistent salivary gland swelling, Theander et al. [72]
and Coiffier et al. [77] stated that SGUS can identify patients at risk of developing lymphoma. However,
these results were found in retrospective cohorts, and longitudinal studies should be performed to
assess whether SGUS findings are predictive of lymphoma [78]. Furthermore, the capability of SGUS
to detect lymphoma compared to histopathology and MRI should be clarified.
The studies presented thus far provide evidence that SGUS has added value in the diagnostic
work-up of pSS (Table 2). Further research should be performed on the development of a consensus
scoring system. Furthermore, to assess the usefulness of SGUS in follow-up and lymphoma detection
in pSS, longitudinal studies are needed. Several initiatives have started already, such as OMERACT
and HarmonicSS projects, which will give us more insight into the potential of this imaging tool in pSS.
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5. Sialendoscopy
Sialendoscopy is a minimally invasive technique used for both diagnosis and management of
obstructive salivary gland disorders, such as sialolithiasis, anatomic ductal abnormalities and mucus
plugs. With this gland-sparing technique, a sialendoscope is entered through the ductal orifice of major
salivary glands for inspection and irrigation of the ductal system, after local or general anesthesia.
In pSS patients, sialendoscopic examination mainly shows strictures, but mucous plugs and
a pale, minimally vascularized ductal wall of the larger excretory ducts can also be observed [79–81].
Ductal strictures can cause ductal obstruction and could therewith account for glandular swelling and
pain in pSS. It is still unclear what these strictures reflect at a histological level. One hypothesis is
that strictures are caused by large LELs that obstruct the ductal system, but no histological studies
have been performed yet to prove this hypothesis. Since the sialendoscopic findings in pSS are not
specific for the disease, the diagnostic value of this technique in pSS is limited. However, various
studies show that dilatation of strictures in combination with irrigation of the ductal system with
saline and/or corticosteroids by using sialendoscopy is a safe and effective treatment option for
salivary gland dysfunction in pSS patients. Studies showed that both subjective and objective oral
dryness improved after sialendoscopy [80,82,83]. Furthermore, visual analogue scale pain scores
decreased after the procedure [79,84], and the number of episodes of glandular swelling declined
after treatment [85]. However, the above mentioned (pilot) studies included relatively small numbers
of patients. The clinical benefits for pSS patients after sialendoscopy should be further explored in
larger cohorts.
Although complications, such as infections and postoperative pain, seem to be limited [86],
multiple studies reported that the sialendoscopic procedure was not successful in all pSS patients
because of technical issues [79,80]. The most common difficulties reported were problems with
identification or dilatation of the papilla before introducing the sialendoscope, which occurred more
often during sialendoscopy of the submandibular gland compared to the parotid gland. These problems
might be associated with characteristic features of severe stages of pSS, such as the presence of extreme
hyposalivation and atrophic changes. Using salivary gland ultrasonography to assess the stage of
the disease was suggested to predict whether patients would benefit from sialendoscopic treatment [80].
It would be of value to study this suggestion.
In summary, although sialendoscopy has no added value in the diagnostic work-up of pSS, recent
studies have drawn attention to the fact that rinsing the ductal system, a procedure that accompanies
sialendoscopy, might be useful in the management of oral symptoms.
6. Nuclear Medicine Techniques
6.1. Conventional Nuclear Medicine
Nuclear medicine imaging uses specific radiopharmaceuticals to visualize (patho)physiological
processes in the body. Imaging with a a gamma camera system that provides two-dimensional
planar images forms the basis of conventional nuclear medicine. However, it is often difficult to
determine the exact location of increased tracer uptake by using these two-dimensional images.
Three-dimensional images can be created by collecting images from different angles around the patient.
This technique, called single photon emission computed tomography (SPECT), leads to a higher
contrast and improves sensitivity, compared to two-dimensional nuclear medicine. Combining SPECT
with a low dose or contrast-enhanced CT scan enables determination of the exact location of the area
with increased uptake.
6.1.1. 99mTc-Pertechnetate Scintigraphy
Scintigraphy of the major salivary glands is a nuclear imaging technique that evaluates salivary
gland function by uptake and secretion patterns of the radioactive tracer Technetium-99m pertechnetate
(99mTc-pertechnetate). 99mTc-pertechnetate is actively taken up by salivary gland epithelial cells,
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probably by using Na+/I− symporters, and secreted into the ductal lumen along with saliva [87].
The technique was included in previous classification criteria of pSS, in which a positive scintigraphy
was defined as delayed uptake, reduced concentration, and/or delayed excretion of the tracer [16].
However, due to the low specificity and the inability to differentiate uptake failure from secretory
failure, scintigraphy was omitted from the ACR-EULAR classification criteria [14,88]. Various studies
stated that scintigraphic examination should focus on the degree of salivary gland dysfunction in pSS,
instead of the differentiation between pSS and non-SS [31,89].
Several studies found a relationship between scintigraphic findings and severity of the disease.
Brito-Zéron et al. [90] concluded that severe scintigraphic patterns were a prognostic factor for
developing extraglandular manifestations. In a large retrospective study by Ramos-Casals et al. [89],
patients presenting with severe involvement of the salivary glands according to the scintigraphic
examination not only showed increased risk of developing serious extraglandular manifestations, but
also a higher risk of developing lymphoma and a lower survival rate. The latter authors also reported
that scintigraphic findings worsened during follow-up in 32% of patients. This subgroup of patients
also had higher prevalence of high ANA titers, compared to patients with stabilization or improvement
of scintigraphy [89]. Furthermore, scintigraphy was associated with histopathological findings within
labial salivary glands of pSS patients, as scintigraphic parameters decreased significantly with higher
stages of lymphocytic infiltrates graded by Chisholm and Mason’s grading system [91–93].
6.1.2. Future Promising Scintigraphic Tracers
Another scintigraphic tracer studied in pSS patients is 99mTc-EDDA/Tricine-HYNIC-
Tyr(3)-Octreotide (99mTc-HYNIC-TOC). This tracer binds to somatostatin receptors on cell membranes.
These receptors were shown to be overexpressed in various inflammatory and autoimmune diseases,
and were found on, among others, activated lymphocytes, endothelial cells, and the monocyte lineage
in synovium of rheumatoid arthritis (RA) patients [94–96]. Anzola et al. [97] showed increased
99mTc-HYNIC-TOC uptake within salivary glands of pSS patients compared to controls, as well
as a considerably higher sensitivity of 99mTc-HYNIC-TOC scintigraphy compared to conventional
scintigraphy. Furthermore, they demonstrated that 99mTc-HYNIC-TOC scintigraphy was able to
identify joint involvement in a cohort of 62 pSS patients, of which many patients (87%) reported joint
pain. Another tracer with potential applicability for pSS is 99mTc labeled with rituximab, which is
an anti-CD20 tracer that images B-lymphocytes. In a small experimental setting, this tracer showed
variable uptake in salivary glands and moderate uptake in lacrimal glands in two pSS patients [98].
Together, 99mTc-pertechnetate scintigraphy is in many institutes no longer used as an imaging
technique in the diagnostic work-up and follow-up of pSS. Although promising new scintigraphic
tracers have been developed, conventional nuclear medicine has disadvantages, such as the limited
resolution of 8-10 mm and the inability to quantify the exact uptake. Positron emission tomography
(PET), combined with low dose or contrast-enhanced CT, has multiple advantages over conventional
scintigraphy, such as better spatial resolution, faster imaging tracts, and the possibility to quantify
tracer uptake. It would be of value to couple the promising tracers that are mentioned above to a PET
radionuclide in order to study the added value of these PET tracers in pSS patients.
6.2. Positron Emission Tomography/Computed Tomography
PET is an imaging tool developed in the 1990s to visualize specific (patho)physiological processes
of a particular area or of the whole body. The technique is based on injection of radioactive tracers,
which are tracers attached to radionuclides that emit positrons (positively charged electrons) to become
stable. Emitting positrons cannot exist freely and annihilate with antimatter (negatively charged
electrons) by emitting two gamma-ray photons, each with the same energy (511 keV) in direct opposite
directions. The PET camera system consists of a ring-shaped detector system which can detect the two
photons when they arrive within a certain time frame. Recent developments in software of PET
cameras have led to a correction method for the time these photons need to travel to the detector,
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the so-called Time-of-Flight technique. This improvement (since 2005) caused a higher efficacy in
detecting photons. Since then, the use of PET imaging for clinical and research purposes increased
considerably. Although PET was originally used in oncological diseases to detect malignancies,
the usefulness of PET to image infection and inflammation has markedly increased during the last
decade, and PET techniques evolved rapidly. Hybrid camera systems were developed to combine PET
findings with CT or MRI to add anatomical information. These new camera systems provide better
spatial resolution images (around 3–4 mm), decrease scan duration and radiation dose, and lead to
increased diagnostic accuracy. Furthermore, the development of guidelines to standardize PET/CT
techniques between centers by the European Association of Nuclear Medicine (EANM) enhances
comparability of data and promotes multicenter research [99,100]. In addition, new and specific tracers
to image infectious and inflammatory diseases are constantly being developed.
6.2.1. 18F-FDG-PET/CT
The most commonly used PET tracer is 18F-fluorodeoxyglucose (FDG). Uptake of this tracer is
relatively higher in cells that are metabolically active, such as inflammatory cells. FDG is indicated
in several infectious and inflammatory diseases and is useful for the diagnosis and follow-up of
various autoimmune diseases [4,101,102]. In pSS patients, several case reports showed abnormal FDG
uptake in salivary glands [103–105] (Figure 5). However, physiological FDG accumulation in salivary
glands is highly variable, and subjects without known head and neck pathology frequently show
increased FDG uptake in the salivary glands [106,107]. A possible explanation for the wide range in
physiological uptake is that salivary glands of different subjects utilize different amounts of glucose
for metabolism [108,109]. Which human salivary gland cells have the highest glucose uptake is not
known, but in rodent salivary glands, both acinar and ductal cells seem to play a role in glucose
uptake [110,111].
Figure 5. FDG-PET uptake patterns within the parotid glands. FDG-PET/CT showing (A) no increased
uptake in the parotid glands of a subject without pathology in the head/neck region, (B) increased
uptake in both parotid glands in a pSS patient, and (C) intense uptake in both parotid glands of a pSS
patients with histologically confirmed parotid salivary gland MALT lymphoma.
Whether pSS patients show increased FDG uptake in inflamed salivary and lacrimal glands is not
yet clear. Although Cohen et al. [112] reported increased FDG uptake in salivary glands of pSS patients
compared to a control group of patients who underwent PET for an isolated pulmonary nodule, another
study could not confirm this finding [36]. However, both studies used different scoring methods and
camera settings, and standardized guidelines and EANM Research Ltd. (EARL) reconstructions were
not applied in these studies.
Besides visualizing salivary gland inflammation, several authors reported the ability of
FDG-PET/CT to detect systemic disease activity in pSS [104,105,112–115]. Abnormal FDG uptake was
observed in 75–85% of pSS patients, mainly within salivary glands, lymph nodes, and lungs [112,113].
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However, not all organ involvement in pSS can be visualized by FDG-PET/CT, such as neuropathies,
cutaneous vasculitis, and other skin abnormalities, which is mainly due to limited spatial resolution
of PET cameras. Since the optimal spatial resolution is around 3-4 mm in newer PET/CT systems, it
would be of interest to use these newer systems to study the effectiveness of FDG-PET/CT in assessing
systemic disease activity in representative pSS cohorts.
The applicability of FDG-PET/CT in MALT lymphomas is still controversial due to variable
FDG avidity at different MALT locations. Pulmonary and head/neck MALT lymphomas seem to
be most FDG avid, and FDG-PET/CT shows higher sensitivities at these regions [116,117]. Since
pSS-associated MALT lymphomas frequently develop in the salivary glands and/or lungs, there
may be a role for this technique in the detection of lymphomas associated with pSS [113,118,119]
(Figure 3). Cohen et al. [112] reported a higher maximum standardized uptake value (SUVmax) in
lymphoma patients compared to pSS patients without lymphoma. Since only four lymphoma patients
were included in this retrospective cohort, the study was not powered to affirm the usefulness of
FDG-PET/CT in the diagnosis of pSS-associated MALT lymphoma. In another retrospective study
by Kerean et al. [113], 8 out of 15 pSS patients had confirmed salivary gland or pulmonary MALT
lymphoma. They found that a SUVmax of ≥4.7 in the parotid glands and presence of focal lung lesions
were associated with lymphoma. An important advantage of FDG-PET/CT is the possibility to detect
extraglandular lymphoma locations by using whole-body imaging. In addition, Kerean et al. [113]
showed that FDG-PET/CT is useful for biopsy guiding and for treatment response monitoring [113].
However, the mentioned SUVmax threshold found in this study cannot directly be used by others,
as different nonstandardized camera systems were used in this multicenter study. Importantly, both
retrospective studies state that the frequent presence of benign lymph node uptake in pSS patients
can be misleading and should be taken into account when using FDG-PET/CT for the diagnosis of
lymphoma in pSS patients [112,113].
6.2.2. Future Promising PET Tracers
Similar to conventional scintigraphy, specific PET tracers can be used to visualize inflammation
in pSS. A case report showed intense uptake of 68Ga-pentixafor, a radioligand of the chemokine
receptor CXCR4. This receptor is involved in, among others, migration of leukocytes toward sites
of inflammation. In this pSS patient, the increased uptake in salivary glands and lymph nodes was
histologically proven to be attributed to inflammatory cell infiltration [120]. To further investigate
the overexpression of somatostatin receptors in salivary glands and joints of pSS patients, as shown by
99mTc-HYNIC-TOC scintigraphy, the specific PET tracer 68Ga-DOTATOC can be used [121]. Another
pathological feature in pSS that could be visualized is the increased number of B-lymphocytes within
salivary glands. Furthermore, by using whole-body B-lymphocyte imaging, not only B-lymphocytes
within the salivary glands can be visualized, but also B-lymphocytes that are present in other
organs associated with pSS. We previously showed that high numbers of B-lymphocytes within
salivary glands of pSS patients predict response to rituximab (anti-CD20) therapy [122]. Whole-body
imaging of B-lymphocytes could be an improved and noninvasive method to select pSS patients
who are likely to respond to rituximab treatment. In rheumatoid arthritis and orbital inflammatory
diseases, imaging of B-lymphocytes by using 89Zr-rituximab has shown potential in the detection of
B-lymphocyte-mediated diseases, in the evaluation of rituximab treatment, and also in the selection of
rituximab responders [123,124]. Therefore, it is of interest to study whole-body B-lymphocyte imaging
by using PET/CT in pSS patients, and to assess whether this specific PET tracer can detect treatment
response and can identify rituximab responders at baseline. Since T-lymphocytes are thought to be
predominant in salivary glands in early stages of pSS [125], imaging of these lymphocytes could also be
of added value. Radiolabeled interleukin-2 (IL-2) can detect activated T-lymphocytes within affected
organs in pSS since IL-2 receptors are overexpressed on activated T-lymphocytes [126].
Overall, PET seems to be a promising imaging technique in pSS. Although the added value of
PET in the diagnostic process of pSS remains to be shown, FDG-PET/CT was found to be useful in
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the assessment of disease activity, the systemic staging of pSS-associated lymphomas, and the evaluation
of treatment response.
7. Conclusions
Currently, various imaging techniques are used in the diagnostic work-up and follow-up of
pSS patients, but none of them are included in the current 2016 ACR-EULAR classification criteria.
Although sialography and scintigraphy have been part of previous classification criteria sets, both
techniques are not commonly used in the diagnostic work-up of pSS anymore. An imaging technique
that has proven to be of added value in diagnosing and classifying pSS is SGUS. The next step is to
incorporate a consensus SGUS scoring system into the 2016 ACR-EULAR criteria, after its validation in
independent cohorts. In addition, longitudinal observational studies and clinical trials are needed
to understand the usefulness of SGUS in assessing disease activity and disease progression in pSS.
Several initiatives were started already, such as OMERACT and HarmonicSS, which will give us
more insight into the potential of this promising imaging tool in pSS. Another emerging technique in
the evaluation of salivary gland and systemic involvement in pSS is PET, combined with CT or MRI.
Additional studies are needed to further elucidate the presumed role of FDG-PET/CT in pSS, by using
larger and representative cohorts, standardized scanning procedures, and harmonization between
centers. Besides, new pSS-specific PET tracers should be further explored since they may provide
promising insights into pathological processes. Regarding imaging of pSS-associated lymphomas,
findings on MRI, SGUS, and FDG-PET/CT should be compared to histopathological findings in
order to investigate which imaging technique is most appropriate for the detection and staging of
pSS-associated lymphomas. Furthermore, it is still not known what the various imaging findings in
salivary glands of pSS patients represent at a histological level. Further research, for example, by
performing ultrasound-guided biopsies, is needed to answer this question.
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